
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8072815/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Banff consensus recommendations for steatosis assessment in donor livers. Hepatology, 2022, 75, 1014-1025.	7.3	25
2	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. Journal of Hepatology, 2022, 76, 1030-1041.	3.7	74
3	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). Canadian Liver Journal, 2022, 5, 61-90.	0.9	7
4	Genomic and transcriptomic somatic alterations of hepatocellular carcinoma in non-cirrhotic livers. Cancer Genetics, 2022, 264-265, 90-99.	0.4	3
5	Fifty years of impact on liver pathology: a history of the Gnomes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 191-200.	2.8	Ο
6	NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology, 2021, 73, 2028-2038.	7.3	86
7	Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	21
8	Liver‧pecific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer. Hepatology, 2021, 74, 1203-1219.	7.3	57
9	Hepatocellular adenomas: the expanding epidemiology. Histopathology, 2021, 79, 20-22.	2.9	4
10	Inhibition of chylomicron assembly leads to dissociation of hepatic steatosis from inflammation and fibrosis. Journal of Lipid Research, 2021, 62, 100123.	4.2	3
11	Deep learning quantification of percent steatosis in donor liver biopsy frozen sections. EBioMedicine, 2020, 60, 103029.	6.1	32
12	Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology, 2019, 70, 522-531.	7.3	106
13	Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. PLoS ONE, 2019, 14, e0221683.	2.5	57
14	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Network Open, 2019, 2, e1912565.	5.9	230
15	cHCCâ€CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology, 2018, 68, 113-126.	7.3	244
16	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, 67, 328-357.	7.3	4,738
17	Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology, 2018, 67, 858-872.	7.3	112
18	Hepatocellular carcinoma: Where are we in 2018?. Current Problems in Surgery, 2018, 55, 450-503.	1.1	2

#	Article	IF	CITATIONS
19	Challenges in the hepatic histopathology in non-alcoholic fatty liver disease. Gut, 2017, 66, 1539-1540.	12.1	14
20	Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation. Journal of the American College of Surgeons, 2017, 225, 28-40.	0.5	24
21	Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology, 2017, 65, 1543-1556.	7.3	110
22	Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation. International Journal of Molecular Sciences, 2016, 17, 97.	4.1	65
23	Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. Brain, 2016, 139, 2909-2922.	7.6	114
24	Terminal hepatic venule injury in liver biopsies of allogeneic haematopoietic stem cell recipients—a study of 63 cases. Histopathology, 2016, 68, 996-1003.	2.9	4
25	Acidophil bodies in nonalcoholic steatohepatitis. Human Pathology, 2016, 52, 28-37.	2.0	8
26	Nonalcoholic fatty liver disease. Nature Reviews Disease Primers, 2015, 1, 15080.	30.5	612
27	Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1468-1473.	4.9	9
28	Ciliated hepatic foregut cyst: a report of 6 cases and a review of the English literature. Diagnostic Pathology, 2015, 10, 81.	2.0	32
29	Anatomic Pathology of Hepatocellular Carcinoma. Clinics in Liver Disease, 2015, 19, 239-259.	2.1	22
30	Well-differentiated hepatocellular neoplasm of uncertain malignant potential—reply. Human Pathology, 2015, 46, 635-636.	2.0	6
31	Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress. Hepatic Oncology, 2015, 2, 255-273.	4.2	38
32	Inhibiting Monoacylglycerol Acyltransferase 1 Ameliorates Hepatic Metabolic Abnormalities but Not Inflammation and Injury in Mice. Journal of Biological Chemistry, 2014, 289, 30177-30188.	3.4	40
33	Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis. Modern Pathology, 2014, 27, 420-432.	5.5	33
34	Pathological Features of Fatty Liver Disease. Gastroenterology, 2014, 147, 754-764.	1.3	296
35	Histological Abnormalities in Children with Nonalcoholic Fatty Liver Disease and Normal or Mildly Elevated Alanine Aminotransferase Levels. Journal of Pediatrics, 2014, 164, 707-713.e3.	1.8	146
36	Well-differentiated hepatocellular neoplasm of uncertain malignant potential: proposal for a new diagnostic category. Human Pathology, 2014, 45, 658-660.	2.0	58

#	Article	IF	CITATIONS
37	Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 2121-2130.e2.	4.4	97
38	Role of liver biopsy in nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 9026-37.	3.3	166
39	A novel genetic marker of liver disease aetiology in hepatocellular carcinoma: culling the metabolic syndrome. Gut, 2013, 62, 808-809.	12.1	4
40	Histopathologic features of hepatocellular carcinoma. Clinical Liver Disease, 2012, 1, 194-199.	2.1	18
41	Nonalcoholic Fatty Liver Disease: What the Pathologist Can Tell the Clinician. Digestive Diseases, 2012, 30, 61-68.	1.9	41
42	Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. Journal of Hepatology, 2011, 55, 654-659.	3.7	260
43	Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology, 2011, 53, 810-820.	7.3	941
44	Non-alcoholic fatty liver disease: what's new under the microscope?. Gut, 2011, 60, 1152-1158.	12.1	31
45	Hepatic Progenitor Cell Proliferation and Liver Injury in αâ€1â€Antitrypsin Deficiency. Journal of Pediatric Gastroenterology and Nutrition, 2010, 51, 626-630.	1.8	24
46	Histopathology of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2010, 16, 5286.	3.3	332
47	Pathology of nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 195-203.	17.8	417
48	Gender dimorphic formation of Malloryâ€Denk bodies and the role of xenobiotic metabolism and oxidative stress. FASEB Journal, 2010, 24, 757.7.	0.5	0
49	Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology, 2009, 49, 809-820.	7.3	335
50	Reply:. Hepatology, 2009, 49, 2127-2128.	7.3	0
51	Reply:. Hepatology, 2009, 50, 321-322.	7.3	0
52	Histopathology of Non-Alcoholic Fatty Liver Disease. Clinics in Liver Disease, 2009, 13, 533-544.	2.1	116
53	Ballooned hepatocytes in steatohepatitis: The value of keratin immunohistochemistry for diagnosis. Journal of Hepatology, 2008, 48, 821-828.	3.7	218
54	Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005, 41, 1313-1321.	7.3	8,518

#	Article	IF	CITATIONS
55	Infarction in Focal Nodular Hyperplasia of the Liver: A Case Report. American Journal of Clinical Pathology, 1991, 95, 503-506.	0.7	17
56	Fulminant hepatic failure after repeated exposure to isoflurane anesthesia: A case report. Hepatology, 1991, 13, 1017-1021.	7.3	70
57	Fulminant hepatic failure caused by acute fatty liver of pregnancy treated by orthotopic liver transplantation. Hepatology, 1990, 11, 59-64.	7.3	122
58	Comparison of Culture and Serology for the Diagnosis of Cytomegalovirus Infection in Kidney and Liver Transplant Recipients. Journal of Infectious Diseases, 1990, 161, 454-461.	4.0	87